Received Jul 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | 2 | G22GH | — |
two doses administered to the same patient; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 69-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number G22GH, expiry date 01-JUL-2025) for prophylaxis. Previously administered products included Arexvy (received 1st dose on 23-AUG-2023 with batch number: 9B2Y4 and expiry date: 20-JAN-2024). On 06-SEP-2024, the patient received the 2nd dose of Arexvy. On 06-SEP-2024, an unknown time after receiving Arexvy, the patient experienced extra dose administered (Verbatim: two doses administered to the same patient). The outcome of the extra dose administered was not applicable. Additional Information: GSK receipt date: 16-JUL-2025 The pharmacist called to ask for information about the administration of two doses of Arexvy to the same patient which led to extra dose administered. No further information was obtained in this call. The vaccine administration facility was the same as primary reporter.